ATOS Stock Summary and Trading Ideas (Atossa Therapeutics | NASDAQ:ATOS)

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.

Atossa Therapeutics trades on the NASDAQ stock market under the symbol ATOS.

As of September 25, 2026, ATOS stock price declined to $1.90 with 77,377 million shares trading.

ATOS has a beta of 1.60, meaning it tends to be more sensitive to market movements. ATOS has a correlation of 0.04 to the broad based SPY ETF.

ATOS has a market cap of $18.95 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ATOS traded as high as $34.65 and as low as $1.70.

The top ETF exchange traded funds that ATOS belongs to (by Net Assets): VTI, VXF, IWC.

ATOS has underperformed the market in the last year with a price return of -84.5% while the SPY ETF gained +18.4%. However, in the short term, ATOS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +7.3% vs +5.3% return in SPY. But in the last 2 weeks, ATOS shares have been beat by the market, returning -24.3% compared to an SPY return of +1.2%.

ATOS support price is $1.95 and resistance is $2.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATOS shares will trade within this expected range on the day.